Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors

This study has been completed.
Information provided by (Responsible Party):
Baki Topal, University Hospital, Gasthuisberg Identifier:
First received: May 17, 2011
Last updated: July 1, 2012
Last verified: July 2012
Only few reports exist on long-term survival after minimally invasive liver surgery (MILS for colorectal liver metastases. No data are available assessing prognostic factors in the era of current modern treatment strategies. The aim of the current study is to analyze the long-term oncologic outcome after MILS for metastases from colorectal cancer and determine prognostic indicators.

Long-term Oncologic Outcome of MILS in Patients With CRLM and Prognostic Indicators

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Further study details as provided by University Hospital, Gasthuisberg:

Primary Outcome Measures:
  • overall survival [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • prognostic variables [ Time Frame: 5 year ]

Biospecimen Retention:   Samples With DNA
Tissue samples for histopathology diagnosis & staging

Enrollment: 274
Study Start Date: October 2002
Study Completion Date: July 2012
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
patients with colorectal liver metastases (CRLM) who undergo their primary surgery at UZ. Leuven (single-center academic study)


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Consecutive patients sufering from colorectal liever metastases (CRLM) who undergo minimally invasive liver surgery (MILS) or open liver surgery (OLS)

Inclusion Criteria:

  • Patients with CRLM
  • Surgery: resection and/or ablation
  • preoperative chemotherapy and/or biological agents are allowed
  • postoperative chemotherapy and/or biological agents are allowed
  • simultaneous colorectal resection is allowed

Exclusion Criteria:

  • primary liver cancer
  • benign liver tumors
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01356706

University Hospitals Leuven KUL
Leuven, Vlaams-Brabant, Belgium, 3000
Sponsors and Collaborators
University Hospital, Gasthuisberg
  More Information

Responsible Party: Baki Topal, Professor of Surgery, University Hospital, Gasthuisberg Identifier: NCT01356706     History of Changes
Other Study ID Numbers: CRLM-MILS
Study First Received: May 17, 2011
Last Updated: July 1, 2012

Keywords provided by University Hospital, Gasthuisberg:
liver metastases
colorectal cancer
prognosis processed this record on May 22, 2017